Archive for Syntrix Biosystems

Syntrix Clinical Trial of Omnitram Succeeds on Primary Endpoints

Syntrix announced that the Phase 1B study investigating Omnitram for pain in healthy subjects met its primary endpoints for pharmacokinetics, safety, and analgesia.  The study was performed with Syntrix collaborators at PRA International and the IIT Research Institute.  The study was funded by a $1.8 million grant from the National Institute on Drug Abuse (NIDA) […]

Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial for the treatment of Psoriasis with (L/D)-Aminopterin

Congratulations to Syntrix scientists on their new grant for $1.725M from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).  The project title is “Efficacy and Resistance Mechanisms of (L/D)-Aminopterin in Psoriasis.”  Here is the public health relevance from the proposal:  “Psoriasis is a chronic scaly and inflammatory […]

Syntrix Presents at the 2014 ACA Summit in Washington, D.C.

Syntrix was invited to present at the 2014 Angel Capital Association (ACA) Summit co-sponsored by the National Heart Lung and Blood Institute (NHLBI).  This conference brings together businesses, angel investors, and strategic partners from the biotech and pharmaceutical industries. It features presentations by top NHLBI-funded companies with innovative technologies.  The Syntrix presentation featured SX-682, the […]

Syntrix Receives $1.8M Grant to Develop Omnitram for Acute and Chronic Pain

Congratulations to Syntrix scientists on their new grant for $1.8M from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). The project title is “Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers.” Here is the public health relevance from the proposal: “Tramadol is a widely prescribed analgesic, but 10% of the U.S. population is resistant […]

Dr. Zebala Invited to Speak at the 2011-2012 David Rogers Health Policy Colloquium at the Weill Cornell Medical College

Dr. John Zebala, President and CEO of Syntrix Biosystems and alumnus of the Weill Cornell Medical College was an invited speaker at the 2011-2012 David E. Rogers Health Policy Colloquium. Dr. Zebala shared his experience with the current business and regulatory challenges facing early-stage drug development. Learn more about the life of David E. Rogers. 

Collaboration: Syntrix Receives $557K Grant to Develop New Drug for Multiple Drug Resistant Tuberculosis

Syntrix scientists will collaborate with Dr. Andrew Bognar of the University of Toronto on a $557K tuberculosis grant from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The project title is “Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB.” The public health relevance from the proposal: “Multidrug-resistant tuberculosis and extensively drug […]

Syntrix Receives $3.8M Grant to Develop New Treatment for COPD and Lung Disease Affecting Newborns

Congratulations to Syntrix scientists on their new grant for $3.8M from the National Hearth Lung and Blood Institute (NHBLI) of the National Institutes of Health (NIH). The project title is “Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD.” Here is the public health relevance from the proposal: “Pulmonary inflammatory diseases such as bronchopulmonary dysplasia (BPD) […]

Syntrix Featured in Microsoft Case Study on Technology Development for Spatiotemporal Gene Control

Syntrix research and development program toward developing a spatiotemporal gene control technology was featured in a Microsoft Case Study. Read the article.

Syntrix Reports the Cellular Mechanism of Compounds It Discovered to Treat COPD and Lung Disease in Neonates

Congratulations to Syntrix scientists and their collaborators at Montana State University on their latest publication in The Journal of Pharmacology and Experimental Therapeutics. Signficance: These studies demonstrate that compounds discovered by Syntrix to treat COPD and lung disease in neonates work by inhibiting CXCR1/2, G-protein coupled receptors, via a novel intracellular mechanism. Abstract: The chemokine receptors CXCR1/2 are […]

Syntrix Receives $590K Grant to Develop New Targeted Arthritis Treatment

Congratulations to Syntrix scientists on their new grant for $590K from the National Institute for Arthritis Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). The project will be carried out in collaboration with Dr. Larry Matherly’s group at Wayne State University School of Medicine. The project title is “99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis.” Here […]